TIGIT binds with high-affinity to CD155 (PVR) and with low-affinity to CD112 (PVRL2; nectin-2) which are expressed in the tumor microenvironment (TME) by antigen presenting cells (APCs) and tumor cells (15). Here, NECTIN2 is linked to neoplasm.